Neuropharmacological modulation of cognition

Current Opinion in Neurology

Volumn 19, Issue 6, 2006, Pages 607-612

  Chamberlain, Samuel R ^a,b   Müller, Ulrich ^a,b   Robbins, Trevor W ^b,c   Sahakian, Barbara J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UK   (United Kingdom)

Author keywords

Arousal; Dopamine; Impulsivity; Memory; Noradrenaline; Serotonin

Indexed keywords

ATOMOXETINE; BUSPIRONE; CITALOPRAM; CLONIDINE; GUANFACINE; LEVODOPA; METHAMPHETAMINE; METHYLPHENIDATE; PROPRANOLOL; PSYCHOSTIMULANT AGENT; SEROTONIN; YOHIMBINE;

AMYGDALOID NUCLEUS; ATTENTION; ATTENTION DEFICIT DISORDER; COGNITION; DEPTH PERCEPTION; FLASH BACK; GENETIC POLYMORPHISM; HUMAN; IMPULSIVENESS; NEGLECT; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; PANIC; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; RECALL; REVIEW; SIDE EFFECT; SUBSTANCE ABUSE; TRICHOTILLOMANIA; VISUAL NEGLECT SYNDROME; WORKING MEMORY;

ATTENTION; BIOGENIC MONOAMINES; BRAIN; COGNITION; COGNITION DISORDERS; HUMANS; IMPULSIVE BEHAVIOR; MEMORY, SHORT-TERM; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS;

EID: 33751034432     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000247613.28859.77     Document Type: Review

References (65)

1. Robbins TW. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 2000; 133:130-138.
2. Rubia K, Smith AB, Brammer MJ, et al. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry 2005; 162:1067-1075.
3. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57:1215-1220.
4. Müller U, Fletcher PC, Steinberg H. The origin of pharmacopsychology: Emil Kraepelin's experiments in Leipzig, Dorpat and Heidelberg (1882-1892). Psychopharmacology (Berl) 2006; 184:131-138. A historical account of Emil Kraepelin's early neuropharmacological studies.
5. Sahakian BJ, Morris RG, Evenden JL, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988; 111 (Pt 3):695-718.
6. Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990; 28:1021-1034.
7. Owen AM, Roberts AC, Polkey CE, et al. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 1991; 29:993-1006.
8. Murphy FC, Sahakian BJ, Rubinstein JS, et al. Emotional bias and inhibitory control processes in mania and depression. Psychol Med 1999; 29:1307-1321.
9. Wilder J. Recent developments in the law of initial values. Exp Med Surg 1962; 20:126-131.
10. Mehta MA, Manes FF, Magnolfi G, et al. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology (Berl) 2004; 176 (3-4):331-342.
11. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005; 57:1377-1384. This is an excellent review of the involvement of catecholamines in prefrontal cortex mediated cognitive abilities, showing key findings from the animal literature.
12. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30:1-23. This is a comprehensive and well written review of the literature on Parkinson's disease, L-DOPA treatment, and cognitive functioning, in relation to the inverted 'U'.
13. Soubrié P. Reconciling the role of central serotonin neurons in human and animal behaviour. Behav Brain Res 1986; 9:319-364.
14. Robbins TW. Cortical noradrenaline, attention and arousal. Psychol Med 1984; 14:13-21.
15. Marsden CA. Dopamine: the rewarding years. Br J Pharmacol 2006; 147(Suppl 1):S136-S144.
16. Mobini S, Chiang TJ, Ho MY, et al. Effects of central 5-hydroxytryptamine depletion on sensitivity to delayed and probabilistic reinforcement. Psychopharmacology (Berl) 2000; 152:390-397.
17. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: Translation between clinical and preclinical studies. Clin Psychol Rev 2006; 26:379-395.
18. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976; 33:1193-1197.
19. Linnoila M, Virkkunen M, Scheinin M, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983; 33:2609-2614.
20. Virkkunen M, Rawlings R, Tokola R, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51:20-27.
21. Tyano S, Zalsman G, Ofek H, et al. Plasma serotonin levels and suicidal behavior in adolescents. Eur Neuropsychopharmacol 2006; 16:49-57. This paper emphasizes the likely involvement of serotonin in emotionally salient aspects of impulsivity. Significant negative correlations were found between plasma serotonin levels and suicidal behaviour severity in suicidal inpatients.
22. Evenden JL. Varieties of impulsivity. Psychopharmacology (Berl) 1999; 146:348-361.
23. Aron AR, Fletcher PC, Bullmore ET, et al. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 2003; 6:115-116.
24. Clark L, Robbins TW, Ersche KD, et al. Reflection impulsivity in current and former substance users. Biol Psychiatry 2006; Jan 28 [Epub ahead of print]
25. Lijffijt M, Kenemans JL, Verbaten MN, van Engeland H. A meta-analytic review of stopping performance in attention-deficit/hyperactivity disorder: deficient inhibitory motor control? J Abnorm Psychol 2005; 114:216-222. This is a comprehensive meta-analysis of response inhibition findings in ADHD to date. Impaired response inhibition was found across studies, but was confounded in children (but not adults) by lengthened reaction times.
26. Boonstra AM, Kooij JJ, Oosterlaan J, et al. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? J Clin Exp Neuropsychol 2005; 27:278-298. It is shown here that 3-week methylphenidate treatment improved aspects of sustained attention, objectively assessed, in adults with ADHD. Treatment also improved response inhibition, but only in participants with slow stop-signal reaction times beforehand.
27. Chamberlain SR, Fineberg NA, Blackwell AD, et al. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry 2006; 163:1282-1284. This paper identifies severely impaired response inhibition, according to objective assessment with the stop-signal reaction time task, in un-medicated patients with trichotillomania (repetitive hair pulling). Patients with obsessive compulsive disorder were also impaired, but to a lesser degree. As stop-signal impairment correlated with trichotillomania symptom severity, this cognitive deficit represents an important target for novel pharmacological interventions.
28. Monterosso JR, Aron AR, Cordova X, et al. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 2005; 79:273-277. In this study, chronic methamphetamine abusers (who were 5-7 days abstinent) showed impaired response inhibition, implicating problems in this domain either in the manifestation of, or in the consequences of, substance abuse.
29. Young SN. The use of diet and dietary components in the study of factors controlling affect in humans: a review. J Psychiatry Neurosci 1993; 18:235-244.
30. Clark L, Roiser JP, Cools R, et al. Stop signal response inhibition is not modulated by tryptophan depletion or serotonin transporter polymorphism in healthy volunteers: implications for the 5-HT theory of impulsivity. Psychopharmacology (Berl) 2005; 182:570-578. Contrary to the classical link between serotonin and impulse control, it was shown that depletion of serotonin in healthy volunteers did not affect response inhibition.
31. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci 2004; 8:170-177.
32. Chamberlain SR, Muller U, Blackwell AD, et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol (in press).
33. Chamberlain SR, Muller U, Blackwell AD, et al. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006; 311:861-863. This paper reports a double-dissociation for the involvement of serotonin and noradrenaline in probabilistic learning and response inhibition, using citalopram and atomoxetine.
34. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7:77-97.
35. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46:1234-1242.
36. Cools R, Blackwell A, Clark L, et al. Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity. Neuropsychopharmacology 2005; 30:1362-1373. In this paper, depletion of brain serotonin disrupted reward-related speeding on a task involving emotionally salient reward and feedback, as a function of self-reported impulsivity. This is consistent with serotonin playing a role in affective aspects of impulse control.
37. Roiser JP, Blackwell AD, Cools R, et al., Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion. Neuropsychopharmacology 2006; Mar 15 [Epub ahead of print]. In this healthy volunteer study, it was shown that tryptophan depletion affected reward-related speeding only in participants with the short-short (but not long-long) variant of the serotonin transporter gene, showing that neurochemical manipulations can be dependent upon functional genetic polymorphisms.
38. Foote SL, Aston-Jones G, Bloom FE. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci U S A 1980; 77:3033-3037.
39. Berridge CW, Arnsten AF, Foote SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psychol Med 1993; 23:557-564.
40. Smith A, Nutt D. Noradrenaline and attention lapses. Nature 1996; 380:291.
41. Aston-Jones G. Brain structures and receptors involved in alertness. Sleep Med 2005; 6 (Suppl 1):S3-S7.
42. Coull JT. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998; 55:343-361.
43. Chamberlain SR, Muller U, Blackwell AD, et al. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology (Berl) 2006; Apr 27 [Epub ahead of print] This is a tabulated review of the effects of noradrenergic manipulations on memory processes in healthy volunteers. Implications for posttraumatic stress disorder and other conditions are discussed.
44. Diagnostic and statistical manual of mental disorders IV (DSM-IV). Arlington: American Psychiatric Association; 1994.
45. Llorente AM, Voigt RG, Jensen CL, et al. Performance on a visual sustained attention and discrimination task is associated with urinary excretion of norepineprhine metabolite in children with attention-deficit/hyperactivity disorder (AD/HD). Clin Neuropsychol 2006; 20:133-144. Preliminary findings reported in this paper support a particular role for noradrenaline rather than dopamine in mediating aspects of sustained attention.
46. Turner DC, Blackwell AD, Dowson JH, et al. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2005; 178:286-295. This paper shows that acute methylphenidate improved aspects of cognition in adults with ADHD, including sustained attention.
47. Coull JT, Frith CD, Frackowiak RS, et al. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 1996; 34:1085-1095.
48. Parton A, Coulthard E, Husain M. Neuropharmacological modulation of cognitive deficits after brain damage. Curr Opin Neurol 2005; 18:675-680.
49. Malhotra PA, Parton AD, Greenwood R, et al. Noradrenergic modulation of space exploration in visual neglect. Ann Neurol 2006; 59:186-190. Noradrenergic drugs may be useful in the treatment of visuospatial neglect. It is shown here that guanfacine improved target detection in neglect patients with lesions not affecting the dorsolateral prefrontal cortex.
50. Southwick SM, Brenner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 46:1192-1204.
51. McGaugh JL. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci 2004; 27:1-28.
52. van Stegeren AH, Goekoop R, Everaerd W, et al. Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. Neuroimage 2005; 24:898-909. It is shown here that the b-blocker propranolol reduced neural responses to some types of emotionally salient stimuli. This suggests critical coupling between noradrenergic transmission and the amygdala (and associated regions), with implications for understanding and treating posttraumatic stress disorder.
53. Brozoski TJ, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205:929-932.
54. Robbins TW. Dopamine and cognition. Curr Opin Neurol 2003; 16 (Suppl 2):S1-S2.
55. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos Transact A Math Phys Eng Sci 2004; 362:2871-2888.
56. Gibbs SE, D'Esposito M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl) 2005; 180:644-653. The authors present a prime example of how drug manipulations can be coupled with powerful neuroimaging cognitive paradigms. The authors used a novel fMRI test to investigate the effects of dopaminergic manipulation (in this case, using bromocriptine) on component processes of working memory. Behaviourally, there was evidence that participants with lower baseline memory span scores showed greater improvement on drug, consistent with the inverted 'U' model.
57. Mehta MA, Owen AM, Sahakian BJ, et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20: RC65.
58. Owen AM, Morris RG, Sahakian BJ, et al. Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Brain 1996; 119 (Pt 5):1597-1615.
59. Owen AM, Iddon JL, Hodges JR, et al. Spatial and nonspatial working memory at different stages of Parkinson's disease. Neuropsychologia 1997; 35:519-532.
60. Lewis SJ, Slabosz A, Robbins TW, et al. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005; 43:823-832. In this paper, patients with Parkinson's disease were tested on and off L-DOPA medication. Treatment ameliorated working memory impairments but not attentional set-shifting impairments in these patients.
61. Swainson R, Rogers RD, Sahakian BJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000; 38:596-612.
62. Sahakian B, Joyce E, Lishman WA. Cholinergic effects on constructional abilities and on mnemonic processes: a case report. Psychol Med 1987; 17:329-333.
63. Salmond CH, Chatfield DA, Menon DK, et al. Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain 2005; 128 (Pt 1):189-200.
64. Meyer-Lindenberg A, Nichols T, Callicott JH, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006; Jun 20 [Epub ahead of print].
65. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100:6186-6191.